15 new oncology trials approved in Europe
 |
Oncology Hero |
15 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week.
Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study
| Sponsor: UZ Leuven | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestAntibody-based PET imaging and treatment response in breast cancer treated with an antibody-drug conjugate according to current standard indications.
| Sponsor: Unicancer | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).
| Sponsor: AstraZeneca AB | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
| Sponsor: Glaxosmithkline Research & Development Limited | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
| Sponsor: Glaxosmithkline Research & Development Limited | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Randomized Phase 2/3 Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)
| Sponsor: Summit Therapeutics Inc. | Phase: 2, 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
| Sponsor: Genmab A/S | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestAntibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
| Sponsor: HUS-yhtymae | Phase: 4 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA multicentre, randomized, open label study comparing the concomitant administration of trabectedin and low-dose radiotherapy versus trabectedin alone in patients with advanced sarcoma
| Sponsor: Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz | Phase: 4 |
Interested in offering this trial to suitable patients?
Register Investigator InterestBASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma
| Sponsor: University Of Cologne | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
| Sponsor: Aura Biosciences Inc. | Phase: |
Interested in offering this trial to suitable patients?
Register Investigator InterestA phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer
| Sponsor: Pharmacosmos A/S | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
| Sponsor: Immuneering Corp. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPrevention of Venous Thromboembolism in Patients with Cirrhosis and Hepatocellular Carcinoma
| Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
| Sponsor: Phosprint S.A. | Phase: 1 |
Interested in offering this trial to suitable patients?
Register Investigator InterestOncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL) Sponsor: Oslo Universitetssykehus HF Phase: Not specified Interested in offering this trial to suitable patients? Register Investigator Interest A Phase 3 Randomized Study...
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high Sponsor: UZ Brussel Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Randomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and...
Oncology Hero 10 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study MeetURO and FICOG trial Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori Phase: 3 Interested in offering this trial to suitable patients?...